Novartis Pharma AG: Novartis Fabhalta (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...

Coles backs out of buying $4b Petbarn owner Greencross after negotiation breakdown, sending its share price soaring

Coles has backed out of its plan to purchase the operator of Petbarn for about $4 billion after about nine months of ...

Jasper Therapeutics, Inc. Announces Merger with Kira Pharmaceuticals

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment w ...
MarketWatch

U.S. 1 Month Treasury Bill

U.S. 3 Year Treasury Note 0.0240 4.1680% U.S. 5 Year Treasury Note 0.0530 4.2420% U.S. 7 Year Treasury Note 0.0630 4.3730% ...